Copy Link Print Information

Danuglipron tromethamine

(Synonyms: PF-06882961 tromethamine)
4 Cited Publications
Customer Review

Based on 4 publication(s) in Google Scholar

Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research.

For research use only. We do not sell to patients.

  • CAS No.: 2230198-03-3
  • Formula: C35H41FN6O7
  • Molecular Weight:676.73
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Danuglipron tromethamine Chemical Structure
    Danuglipron tromethamine Chemical Structure
  • Experimental Validation Results for Danuglipron tromethamine
  • Experimental Validation Results for Danuglipron tromethamine
  • Experimental Validation Results for Danuglipron tromethamine
  • Experimental Validation Results for Danuglipron tromethamine
  • Experimental Validation Results for Danuglipron tromethamine
  • Experimental Validation Results for Danuglipron tromethamine
CAS No.: 2230198-03-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Danuglipron tromethamine:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Danuglipron tromethamine

More
Customer Validation & Images
Cell Proliferation/Viability AssayIFRT-PCRIn Vivo Efficacy StudyWB
  • Cell Proliferation/Viability Assay
  • IF
  • RT-PCR
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • WB
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Danuglipron tromethamine Chemical Structure
    Danuglipron tromethamine Chemical Structure
    1/16
  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     (A) NRCMs were treated with different concentrations of Danuglipron (PF; 0, 0.05, 0.1, 0.3, 0.9, and 1.2μg/mL) for 24 h, and cell viability was assessed to determine the dose-dependent effects of PF on cardiomyocyte survival. (B) NRCMs were treated with 0.1μg/mL PF for 0, 12, 24, 48, 72, and 96h, followed by the assessment of cell viability at each time point.

  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     Neonatal rat cardiomyocytes (NRCMs) were treated with 100 μM PE for 24–48 h to induce hypertrophy, with or without co‐treatment with Danuglipron (PF) at the previously determined optimal concentration of 0.1 μg/mL. Representative immunofluorescence images of NRCMs stained for α-actinin (red) under different treatment conditions: PBS (control), PF alone, PE alone, and PE+PF.

  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     Neonatal rat cardiomyocytes (NRCMs) were treated with 100 μM PE for 24–48 h to induce hypertrophy, with or without co‐treatment with Danuglipron (PF) at the previously determined optimal concentration of 0.1 μg/mL. Relative mRNA expression levels of hypertrophy-related markers (ANP, BNP, and β-MHC) in NRCMs under different treatment conditions, as determined by RT-PCR.

  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     Danuglipron (PF; 1, 3, 9 mg/kg; po; daily for 8 weeks was initiated 3 days after AB surgery) in C57BL/6 mice using aortic banding (AB) surgery. Representative M-mode echocardiographic images of left ventricular function in different treatment groups.

  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     Danuglipron (PF; 1, 3, 9 mg/kg; po; daily for 8 weeks was initiated 3 days after AB surgery) in C57BL/6 mice using aortic banding (AB) surgery revealed that hearts from AB mice were significantly enlarged, with hypertrophic cardiomyocytes compared to the sham group. Representative images of gross morphology of mouse hearts (A), (B) H&E-stained cross-sections of the hearts.

  • 1/16

    Danuglipron tromethamine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2025 Mar;29(5):e70488. [Abstract]

    Customer Validation
     Danuglipron (PF; 1, 3, 9 mg/kg; po; daily for 8 weeks was initiated 3 days after AB surgery) in C57BL/6 mice using aortic banding (AB) surgery treatment dose‐dependently increased p‐AMPKα levels in AB mice, with the low dose showing the most pronounced effect. Representative western blot images showing the expression of p-AMPKα, AMPKα, and HSP70 in heart tissues from C57BL/6 mice across different treatment groups. GAPDH serves as a loading control.

  • Danuglipron tromethamine